ClinicalTrials.gg
RecruitingNCT07552402FREEDOMUpdated Oct 28, 2026

Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

An interventional study of Oral Paclitaxel Solution Plus Fruquintinib and Investigator Choice (IC) Chemotherapy in Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, sponsored by Harbin Medical University. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Harbin Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 28, 20269 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies testing paclitaxel in Stomach Neoplasms — 18 open to participants now, 22 under way, 1 of them phase 3. Paclitaxel · Stomach Neoplasms.

Planned enrollment
17th of 89
150 · median 50
Started
2026
with 2 others
No phase
5 of 92
2 open now
Primary completion
2027-12
later than 19 of 21 live
Registered
91st of 92
by date

Among the 92 studies testing paclitaxel in Stomach Neoplasms, this one is the 17th largest by planned enrollment of the 89 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 with no phase, reaches primary completion later than 19 of the 21 other live ones, and was the 91st registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

18 of the 92 studies testing paclitaxel in Stomach Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies testing paclitaxel in Stomach Neoplasms, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

03

Conditions studied

  • Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years, regardless of sex;
  2. and/or cytologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has failed therapy or developed intolerable toxicity to first-line treatment.
  3. Presence of at least one per v1.1 criteria (Note: Previously irradiated lesions cannot be used as target lesions unless unequivocal progression of the lesion after radiotherapy is documented);
  4. Body weight ≥40 kg or >18.5 kg/m²;
  5. No severe hematologic, hepatic, or renal abnormalities:

    1. Hematology: (ANC) ≥1.5×10⁹/L; count (PLT) ≥100×10⁹/L; (Hb) ≥90 g/L;
    2. Chemistry: Total (TBIL) ≤1.5× (ULN); and AST ≤2.5×ULN in the absence of liver , or ≤5×ULN if liver metastases are present; Serum creatinine (Cr) ≤1.5×ULN;
    3. Urinalysis: Urine protein ≤1+; If urine protein is ≥2+, a 24-hour urine protein test must be performed, and enrollment is permitted only if the 24-hour urine protein is \<1.0 g;
  6. Performance Status (PS) 0-1;
  7. ≥12 weeks;
  8. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Known -positive status without prior anti-HER2 therapy (patients who progressed after anti-HER2 therapy are eligible);
  2. History of another primary within 3 years prior to the first study drug administration, except for adequately treated basal cell or squamous cell carcinoma of the skin, or in situ carcinomas of the cervix, breast, or other sites;
  3. Receipt of radiotherapy (except palliative radiotherapy), chemotherapy, or small-molecule targeted anticancer therapy within 4 weeks or within 5 half-lives of the agent (whichever is shorter) prior to the first dose of study drug. Patients who discontinued other agents for more than 5 half-lives are eligible for screening. Additionally, treatment with large-molecule targeted anticancer agents within 4 weeks prior to the first study drug dose is prohibited;
  4. Toxicity from prior anticancer therapy not recovered to ≤ Grade 1 or baseline levels (except alopecia; neurotoxicity must have resolved to ≤ Grade 2) within 2 weeks prior to the first study drug administration;
  5. Presence of dysphagia, uncontrolled nausea, vomiting, diarrhea, or known malabsorption syndrome that may interfere with oral drug absorption;
  6. Active gastrointestinal conditions such as gastric/duodenal ulcer, ulcerative colitis, or bowel obstruction, or any other condition deemed by the investigator to carry a risk of gastrointestinal hemorrhage or perforation; history of gastrointestinal perforation or fistula within the past 6 months; or incomplete recovery from surgery related to gastrointestinal perforation or fistula;
  7. Evidence of significant bleeding or history of bleeding (e.g., hematemesis, hemoptysis) within 2 months prior to randomization. Patients with melena and positive fecal occult blood test must undergo gastroenteroscopy to rule out active bleeding or active ulcer before enrollment;
  8. Requirement for long-term use of proton pump inhibitors (PPIs) or H2-receptor antagonists during the trial; or use of strong inducers or inhibitors of cytochrome P450 (CYP) 3A4 or CYP2C8 within 2 weeks prior to the first study drug dose;
  9. Known active central nervous system (CNS) and/or ;
  10. Active infections or serious infectious diseases, including but not limited to: infection (positive HIV antibody), active hepatitis (active infection defined as positive HCV RNA; HCV antibody-positive but RNA-negative patients are allowed), active infection (HBsAg-positive with HBV DNA >2000 IU/mL), bacteremia, severe pneumonia requiring systemic therapy, or active tuberculosis;
  11. Any of the following cardiovascular conditions: myocardial infarction, unstable angina, congestive heart failure ( Class ≥2), or other cardiac disease within 6 months prior to the first study drug dose; clinically significant abnormalities (e.g., arrhythmias, >450 ms); (LVEF) \<50% on echocardiography; or uncontrolled hypertension despite treatment with ≥2 antihypertensive agents (systolic BP >140 mmHg or diastolic BP >90 mmHg);
  12. Prior systemic therapy targeting VEGF or VEGFR; or prior treatment with paclitaxel, docetaxel, nab-paclitaxel, liposomal paclitaxel, or polymeric micelle paclitaxel;
  13. Known to any component of the investigational product;
  14. Pregnant or lactating women;
  15. Uncontrolled symptomatic pleural, peritoneal, or pericardial effusion requiring repeated drainage. Asymptomatic patients with minimal effusions detected only on imaging and who have not received drainage or other intervention within 2 weeks prior to enrollment are eligible;
  16. Major surgery (e.g., craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dosing, or presence of non-healed surgical wounds, ulcers, or fractures. Patients may be enrolled if the investigator determines they are fit to receive study drug ≥2 weeks post-surgery;
  17. History of deep vein thrombosis, pulmonary embolism, or other significant thromboembolic events within 3 months prior to study entry; ongoing anticoagulation therapy with warfarin, low-molecular-weight heparin, or similar agents. Prophylactic low-dose anticoagulation is permitted if ≤1.5 per inclusion criteria;
  18. Chronic use of nonsteroidal anti-inflammatory drugs (e.g., indomethacin, ibuprofen) or antiplatelet agents (e.g., clopidogrel, ticlopidine, dipyridamole). Low-dose aspirin (≤325 mg/day) is allowed;
  19. Any other condition deemed by the investigator as unsuitable for participation in this study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Oral Paclitaxel Solution Plus Fruquintinib

    Oral paclitaxel solution: 200mg/m2, p.o., bid, on days 1, 8, and 15 of each 28-day cycle. Fruquintinib: 4 mg orally once daily, 3 weeks on/1week off

    Drug: Oral Paclitaxel Solution Plus Fruquintinib

  • Active comparator
    Investigator-Selected Chemotherapy

    Investigator-selected chemotherapy includes injectable taxanes (paclitaxel injection, albumin-bound paclitaxel, docetaxel, etc.), irinotecan, etc., excluding oral paclitaxel solution. Regimens and doses shall be determined by the investigator in accordance with recommendations from current clinical guidelines.

    Drug: Investigator Choice (IC) Chemotherapy

Interventions

  • DrugOral Paclitaxel Solution Plus Fruquintinib

    Drug pages: PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · HMPL-013Studies of HMPL-013HMPL-013 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients received oral paclitaxel plus fruquintinib in 4-week cycles until disease progression, death, unacceptable toxicity, withdrawal of consent, iscontinuation by the investigator or study completion or termination.

  • DrugInvestigator Choice (IC) Chemotherapy

    Investigator' choice of chemotherapy is given until disease progression, death, unacceptable toxicity, withdrawal of consent, iscontinuation by the investigator or study completion or termination.

06

What researchers measure

Primary outcomes

  1. Progression-free survival(PFS)

    Progression-free survival (PFS) is defined as the time from the date of randomization to disease progression per RECIST 1.1 or death due to any cause, whichever occurs first.

    Time frame: assessed up to 1 year

Secondary outcomes

  1. Objective response rate(ORR)

    ORR is defined as the percentage of subjects who have a Complete Response (CR) or Partial Response (PR) per RECIST 1.1

    Time frame: assessed up to 1 year

  2. Disease Control Rate(DCR)

    DCR is defined as the proportion of subjects whose BOR is rated as CR, PR, or stable disease (SD) per RECIST 1.1

    Time frame: assessed up to 1 year

  3. Overall survival(OS)

    OS is defined as the time from the date of randomization to the date of death, regardless of the cause of death.

    Time frame: From randomization until death due to any cause, up to 3 years.

  4. Adverse event

    Use NCI-CTCAE version 5.0 for classification and grading.

    Time frame: From first dose to 30 days post the last dose

  5. Qualtiy of life assesd by EORTC QLQ-C30 v3.0

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status. There are 30 items in total, which can be divided into 15 fields. Five functional scales: physical function, role function, cognitive function, emotional function, social function; Three symptom scales: fatigue, pain, nausea and vomiting; Six individual measures: dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties, and a global quality of life scale. The five functional scales and the global quality of life scale were scored independently. After linear transformation, the scores of all items ranged from 1 to 100, and the higher score, the higher functional level. The symptom scale was also scored independently and linearly transformed into a score from 1 to 100, with higher scores indicating more serious problems or symptoms.

    Time frame: Evaluation from baseline to the 30 days post the last dose

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 18 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 27, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added
Show 9 added (9 China)
  • Fujian Medical University Union Hospital · Fuzhou, China
  • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • The Affiliated Hospital of Inner Mongolia Medical University · Hohhot, China
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • West China Hospital of Sichuan University · Chengdu, China
  • Peking University Third Hospital · Beijing, China
  • The Second Affiliated Hospital of Soochow University · Suzhou, China
  • General Hospital of Ningxia Medical University · Yinchuan, China
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    9 sites added
    Show 9 added (9 China)
    • Fujian Medical University Union Hospital · Fuzhou, China
    • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • The Affiliated Hospital of Inner Mongolia Medical University · Hohhot, China
    • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • West China Hospital of Sichuan University · Chengdu, China
    • Peking University Third Hospital · Beijing, China
    • The Second Affiliated Hospital of Soochow University · Suzhou, China
    • General Hospital of Ningxia Medical University · Yinchuan, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07552402
Lead sponsor
Harbin Medical University
Responsible party
Yanqiao Zhang (Professor, The Second Affiliated Hospital of Harbin Medical University) — Principal investigator
First posted
Apr 27, 2026
Start date
Jun 10, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Yanqiao Zhang
Contact
yanqiaozhang@ems.hrbmu.edu.cn
86-138 4512 0210

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · HMPL-013

Start the discussion